A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy by Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X

Subjects: “…cldn18.2…”
Get full text

Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer by LI Hao, YE Xianhui, ZHOU Junjie, LI Xiaofen

Subjects: “…cldn18.2…”
Get full text

Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma by Jane E. Rogers, Jaffer Ajani

Subjects: Get full text

The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer by Akira Matsuishi, Shotaro Nakajima, Motonobu Saito, Katsuharu Saito, Satoshi Fukai, Hideaki Tsumuraya, Ryo Kanoda, Tomohiro Kikuchi, Azuma Nirei, Akinao Kaneta, Hirokazu Okayama, Kosaku Mimura, Hiroyuki Hanayama, Wataru Sakamoto, Tomoyuki Momma, Zenichiro Saze, Koji Kono

Subjects: Get full text

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma by Christine Brezden-Masley, Pierre O. Fiset, Carol C. Cheung, Thomas Arnason, Justin Bateman, Martin Borduas, Gertruda Evaristo, Diana N. Ionescu, Howard J. Lim, Brandon S. Sheffield, Sara V. Soldera, Catherine J. Streutker

Subjects: Get full text

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer by Keren Jia, Yang Chen, Yu Sun, Yajie Hu, Lei Jiao, Jie Ma, Jiajia Yuan, Changsong Qi, Yanyan Li, Jifang Gong, Jing Gao, Xiaotian Zhang, Jian Li, Cheng Zhang, Lin Shen

Subjects: Get full text

Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

Subjects: “…cldn18.2…”
Get full text

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody by Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci

Subjects: Get full text

Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression by Shengde Liu, Zizhen Zhang, Lei Jiang, Miao Zhang, Cheng Zhang, Lin Shen

Subjects: Get full text

Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers by Jun Wu, Jun Wu, Jinghua Lu, Qiuyue Chen, Haojie Chen, Yongqiang Zheng, Minggang Cheng

Subjects: “…CLDN18.2…”
Get full text

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma by Yufan Huang, Maojin You, Qundan Wu, Ruijia Chen

Subjects: Get full text